GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Debt-to-EBITDA

NEO (NeoGenomics) Debt-to-EBITDA : -23.96 (As of Mar. 2025)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NeoGenomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $204.2 Mil. NeoGenomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $400.6 Mil. NeoGenomics's annualized EBITDA for the quarter that ended in Mar. 2025 was $-25.2 Mil. NeoGenomics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was -23.96.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NeoGenomics's Debt-to-EBITDA or its related term are showing as below:

NEO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6503.02   Med: 3.84   Max: 20.35
Current: -6503.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of NeoGenomics was 20.35. The lowest was -6503.02. And the median was 3.84.

NEO's Debt-to-EBITDA is ranked worse than
100% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.805 vs NEO: -6503.02

NeoGenomics Debt-to-EBITDA Historical Data

The historical data trend for NeoGenomics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Debt-to-EBITDA Chart

NeoGenomics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.64 13.18 -7.42 -34.74 -400.62

NeoGenomics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.67 200.57 85.25 41.08 -23.96

Competitive Comparison of NeoGenomics's Debt-to-EBITDA

For the Diagnostics & Research subindustry, NeoGenomics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Debt-to-EBITDA falls into.


;
;

NeoGenomics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NeoGenomics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(204.158 + 401.176) / -1.511
=-400.62

NeoGenomics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(204.206 + 400.575) / -25.244
=-23.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


NeoGenomics  (NAS:NEO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


NeoGenomics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Executives
Michael Aaron Kelly director C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Stephen M Kanovsky director 88 OLD YORK ROAD, NEW HOPE PA 18938
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912